Transcenta
Presence
Transcenta is a company listed under the stock ticker 6628 (CN).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Transcenta
- Xueming Qian, Chief Executive Officer
- Helen Chen, Independent Non-Executive Director
- Jiasong Tang, Independent Non-Executive Director
Create your alert
to follow the executive moves at Transcenta.
Biotechnology
Transcenta has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Transcenta
- Transcenta Announces Collaboration with Agilent to Develop a Claudin 18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Presents Osemitamab (TST001) and TST003 Study Results at AACR 2024-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta to Present Two Clinical Trial Progress at ASCO 2023-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients-TRANSCENTA HOLDING - A Gl
- Transcenta Presents Two Preclinical Studies at AACR 2023-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta’s Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta to Present Two Preclinical Studies at AACR 2023-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- View more press releases Close
Social media about Transcenta
- Transcenta on Wikipedia, Google News & Yahoo Finance
- Transcenta on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Xueming Qian 
